Andrew S. Plump MD, PhD

Andrew Plump, M.D., Ph.D., joined Takeda as Chief Medical and Scientific Officer (CMSO). Dr. Plump also serves as a member of Takeda’s Executive Team and of the company’s Board of Directors. In his position, he leads Takeda’s global Research & Development organization, where he provides strategic direction and oversight.

Dr. Plump brings an unwavering focus on patients and a deep commitment to innovation and positive change in the healthcare industry. To continue and accelerate Takeda’s R&D successes, he leads an organization that focuses on people and partnerships, modality diversification, and translational medicine and genomics. Prior to Takeda, Dr. Plump served as Senior Vice President, Research & Translational Medicine, Deputy to the President of R&D at Sanofi, where he was responsible for global research and translational medicine across all therapeutic areas.

Dr. Plump also spent more than 10 years at Merck in a Clinical Pharmacology group, working on programs in neurodegeneration, immunology, metabolism, and infectious diseases. Following additional roles focusing on early development, genomics and biomarkers, particularly in cardiovascular and metabolism, he assumed the position of Vice President, Worldwide Cardiovascular (CV) Research Head. In this role, he had direct responsibility for preclinical development and research teams, and a leadership role in the end-to-end activities of the Merck cardiovascular portfolio. Together with his team, he helped discover and support a pipeline of novel therapies in atherosclerosis, vascular diseases, and thrombosis.